While prevalence rates of psoriasis are lower among the Latino population compared with the white and black populations in the United States, Latinos are shown to be disproportionately affected by poorer quality of life and intensified disease severity, according to study findings.
While prevalence rates of psoriasis are lower among the Latino population compared with the white and black populations in the United States, Latinos are shown to be disproportionately affected by poorer quality of life and intensified disease severity, according to study findings published in the American Journal of Clinical Dermatology.
Current evidence suggests that there are notable differences in the severity of psoriasis between racial and ethnic groups, but as the study authors note, there is little research on the various factors affecting disease severity in the rapidly growing US Latino population. To improve knowledge of psoriasis within this minority group, researchers conducted a review evaluating the current evidence on psoriasis in US Latinos, providing information on factors such as prevalence, severity, and quality of life.
Using data from the National Health and Nutrition Examination Survey, Latinos were shown to have a reduced psoriasis prevalence (1.6%) compared with white (3.7%) and black (2%) patients. Although white patients have a higher prevalence of psoriasis, recent data has shown that individuals with darker skin may be more susceptible to more extensive disease involvement, thicker plaques, and more scale than those with lighter skin.
Compared with white patients, psoriasis was found to affect the US Latino population with more disease severity and a greater quality-of-life impact, which study authors wrote may be attributed to delayed diagnosis and being less likely to seek or receive care for the disease. Medications tailored toward psoriasis showed a noninferior or better response to systemic treatments among Latino cohorts, indicating the potential significance of treatment accessibility and willingness to seek care.
Latinos with psoriasis additionally exhibited higher rates of comorbidities, such as depression, obesity, and diabetes, compared with white patients, which may contribute to the reduced quality-of-life findings.
Researchers speculated that the lack of information on psoriasis within the Latino population may be related to cultural, socioeconomic, and educational barriers to care and clinical trial participation. “Many confounding variables, such as independently high rates of Latino obesity, also impact the reported severity of disease and the resulting comorbidity data available,” they wrote.
The study authors also noted that future studies that reflect the growing proportion of minorities in the United States may assist in bridging the gap of knowledge and improve care within communities, as well as employing techniques to boost clinical trial participation. “Learning unique Latino cultural considerations and overcoming logistical challenges, such as providing Spanish translators and Spanish educational materials, and offering after-hours clinics may begin to address solutions within the scope of our field,” the authors wrote.
Reference
Ashbaugh AG, Ekelem C, Landaverde Y, et al. Psoriatic disease in the US Latino population: a comprehensive review [published online December 16, 2019]. Am J Clin Dermatol. doi: 10.1007/s40257-019-00498-8.
Clinical Characteristics, Outcomes of Patients With Plaque Psoriasis on Tapinarof Cream
December 5th 2023Two posters presented at the 2023 Fall Clinical Dermatology Conference examined patient demographics, clinical characteristics, and outcomes in patients with plaque psoriasis treated with tapinarof cream.
Read More
Psoriasis as an Inflammatory Disease, and What’s Changed Over Time
August 3rd 2021August is National Psoriasis Awareness Month, and on this episode of Managed Care Cast, we bring you an excerpt of an interview with a New Jersey dermatologist about the changing concept of psoriasis as more than just a skin disease.
Listen
Study Finds Link Between Depression, Functional Impairment in Psoriasis, Psoriatic Arthritis
November 24th 2023Depression symptoms are often underdiagnosed and undertreated in patients with psoriasis and psoriatic arthritis, contributing to a worsened quality of life (QOL). However, a recent study found that depression, functional impairment, and worsened QOL are related.
Read More
Evaluating Work Productivity, Efficacy and Safety of Tildrakizumab in Patients With Plaque Psoriasis
November 13th 2023Two posters presented at the 2023 Fall Clinical Dermatology Conference assessed phase 4 study findings on tildrakizumab in patients with moderate to severe plaque psoriasis.
Read More
Evaluating Label Warnings, Switching Rates in Patients With Psoriasis Initiating New Treatment
November 9th 2023Posters presented at the 2023 Fall Clinical Dermatology Conference evaluated how label warnings may affect new treatment initiation and real-word switching patterns for patients starting risankizumab.
Read More